Safety of using the preparation “Licopid®” in opinion of experts in various specialities

Aim. To study the safety of the preparation “Licopid®” using the data, obtained with the method of questioning of doctors of various specialities. The reactant of “Licopid®” tablets is glucoseminylmuramildipeptide – a synthetic analogue of the structural fragment of bacterial cells membrane (peptidoglycan), which is an activator of congenital and acquired immunity;it strengthens the defense of the body from viral, bacterial and fungal infections; it has an adjuvant effect in development of immunological reactions.

Materials and methods. The object of this study were the answers of 2315 specialists to the questions of surveys regarding the safety of using immunomodulator“Licopid®” in their practical activity. The regions, involved into the survey were the following cities: Moscow, Kazan, Krasnodar, Ekaterinburg, St. Petersburg, Chelyabinsk, Novosibirsk, Perm, Samara and Voronezh as well as Krasnodar Krai. Processing of the results was fulfilled with the methods of descriptive statistics; the obtained data were compared with the method based on calculation of chi-square criterion.

Results. The analyzed results showed that 962 respondents (41.5 %) indicated the fact of revealing undesirable reactions (UR) of the preparation “Licopid®” in their own practice. It was noted by them that all undesirable reactions were not severe and predicted, i.e. they were indicated in the instruction for medical use of “Licopid®” 1 mg and 10 mg.

Conclusions. While conducting questioning, the authors revealed statistically significant differences in the structure of respondents’ answers depending on the region of residence and medical speciality. At the same time, for all UR, indicated in instruction, subjectively estimated occurrence rate of reactions coincided with that, declared upon registration, except myalgias and arthralgias, which were noted by doctors much rarely.